This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Brain MRI scans using gadolinium-based contrast agents (GBCAs) have played a central role in diagnosing and monitoring patients with multiple sclerosis (MS).1 GBCAs were initially considered extremely safe.2 Measurable GBCA tissue accumulation has been demonstrated in the dentate nucleus and other CNS structures as increased signal intensity on unenhanced T1-weighted images.3 Due to the potential toxicity of free gadolinium, these reports have raised concern within the scientific community, and among patients with MS and their families. Although no evidence currently exists linking brain gadolinium deposits with clinical consequences, regulatory agencies both in the United States and Europe clearly caution that GBCA should only be administered when informative for patient care.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 248
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis
Dr. Robert Pitceathly and Dr. William Macken
► Watch
Topics Discussed
Alert Me
Recommended articles
Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
A reassessment of the plateauing relationship between T2 lesion load and disability in MS
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study